Use the fields below to search for a publication. The more details you specify, the more accurate your results will be.
Results to display:
Page: 1 of 4
Riggs H, Jalal SI, Baghdadi TA, Bhatia S, McClean J, Johnson C, Yu M, Taber D, Harb W, Hanna N. Erlotinib and Bevacizumab in Newly Diagnosed Performance Status 2 or Elderly Patients With Nonsquamous Non-Small-Cell Lung Cancer, a Phase II Study of the Hoosier Oncology Group: LUN04-77. Clin Lung Cancer. 2012 Oct 24. doi:pii: S1525-7304(12)00201-X. 10.1016/j.cllc.2012.09.004. [Epub ahead of print] PubMed PMID: 23102811
LUN04-77 Published in Clinical Lung Cancer.
Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH. Randomized, Double-Blind, Placebo-Controlled, Phase III Cross-Over Study Evaluating the Oral Neurokinin-1 Antagonist Aprepitant in Combination With a 5HT3 Receptor Antagonist and Dexamethasone
JM Schmitt, SR Sommers, W Fisher, R Ansari, E Robin, K Koneru, J McClean, Z Liu, Y Tong, N Hanna: Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Group: GI06-112 J Thorac Oncol, 2012; 7: 760-763
S. Shadha, M. Yu, J. Picus, J. Bufill, W. Harb, M. Burns, J. Spittler, J. Flynn, Y.Zeng, G. Vance, C. Currie, J. Wu, P. J. Loehrer, E.G. Chiorean. Phase I study of everolimus (RAD001) with Irinotecan (Iri) and Cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Oncology Group GI05-102, final report. Accepted as Poster Presentation at General Poster Session (Abstract # 3587) at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL.
M.J. Brames, J. Picus, M. Yu, E. Johnston, B. Bottema, C. Williams, and L.H. Einhorn. Phase III double blind placebo controlled crossover study evaluating a 5HT3 antagonist + dexamethasone +/- aprepitant in germ cell tumor patients receiving 5 day cisplatin combination chemotherapy. A Hoosier Oncology Group study. Accepted as an Oral Presentation at the Oral Abstract Session (Abstract # 9013) at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL.
B. Leyland-Jones, K. Miller, P. Silverman, C. Shen, C. Williams, T.Breen, G. Sledge. A Phase II Study of Lonafarnib (LF) in Patients with Locally Advanced and Metastatic Breast Cancer (MBC): Hoosier Oncology Group BRE07-126. Accepted as a Poster Presentation (Abstract #598) at the General Poster Session at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL.
D. Bodenmiller, S. Jalal, J. Turchi, J. Wu, Z. Yu, L. Einhorn. A phase I study of Amrubicin (AMR) and Cyclophosphamide in patients with advanced solid organ malignancies: Correlative analysis of a trial from the Hoosier Oncology Group LUN07-130. Accepted as abstract (Abstract # e17517) at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL.
S. R. Malireddy, S.Perkins, S. S. Badve, G. Sledge, and K. Miller. PARP inhibition after preoperative chemotherapy in patients with triple negative breast cancer (TNBC) or known BRCA1/2 mutations: Hoosier oncology group BRE09-146. Accepted as a Poster Presentation (Abstract #TPS130) at the Trials in Progress Session at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL.
T.E. Hutson, J. Sarantopoulos, T. Logan, G. Sonpavde, M.D. Galsky, C. Sweeney, D.C. Bibby, G. Kremmidiotis, E.E. Doolin, N.M. Hahn. Phase I/II study of BNC105P in combination with everolimus or following everolimus for progressive metastatic renal cell carcinoma following prior tyrosine kinase inhibitors. Accepted to the ASCO Annual Meeting, June 4-8, 2011, Chicago, IL.
Download the Poster
Sharma, J., Yiannoutsos, C, Hahn, N., Sweeney, C. "Suppressed markers of bone turnover (BTO) after 6 months of therapy is prognostic for durable prostate cancer control with androgen deprivation therapy (ADT)." Dana Farber Cancer Institute, Indiana University, Hoosier Oncology Group. American Society of Clinical Oncology Meeting, June 2011, Chicago, IL.